Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies

Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) are relentlessly progressive neurodegenerative disorders that are likely to represent two ends of a disease spectrum. It is well established that both are characterised pathologically by widespread cortical Lewy body deposition. However, until recently, the pathophysiological mechanisms leading to neuronal damage were not known. It was also not understood why some cells are particularly vulnerable in PDD/DLB, nor why some individuals show more aggressive and rapid dementia than others. Recent studies using animal and cell models as well as human post-mortem analyses have provided important insights into these questions. Here, we review recent developments in the pathophysiology in PDD/DLB. Specifically, we examine the role of pathological proteins other than α-synuclein, consider particular morphological and physiological features that confer vulnerabilities on some neurons rather than others, and finally examine genetic factors that may explain some of the heterogeneity between individuals with PDD/DLB.

[1]  S. Galetta,et al.  Editors' note: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.

[2]  L. Volpicelli-Daley Effects of α-synuclein on axonal transport , 2017, Neurobiology of Disease.

[3]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[4]  T. Montine,et al.  Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.

[5]  J. Schott,et al.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.

[6]  Jean-François Dartigues,et al.  Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing , 2017, Genome Biology.

[7]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[8]  H. Berendse,et al.  Distribution and Load of Amyloid-&bgr; Pathology in Parkinson Disease and Dementia with Lewy Bodies , 2016, Journal of neuropathology and experimental neurology.

[9]  G. Deuschl,et al.  Abolishing the 1‐year rule: How much evidence will be enough? , 2016, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[11]  Michelle K. Lupton,et al.  Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases , 2016, Neurobiology of Aging.

[12]  S. Murayama,et al.  Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders , 2016, Movement disorders : official journal of the Movement Disorder Society.

[13]  M. Vidailhet,et al.  Sleep aspects on video‐polysomnography in LRRK2 mutation carriers , 2015, Movement disorders : official journal of the Movement Disorder Society.

[14]  H. Reichmann,et al.  Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors , 2015, Nature Reviews Neurology.

[15]  Toshiki Uchihara,et al.  Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies , 2015, Acta Neuropathologica.

[16]  A. Desautels,et al.  GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder , 2015, Annals of clinical and translational neurology.

[17]  W. Schulz-Schaeffer Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson’s Disease? , 2015, Biomolecules.

[18]  Mark P. MacEachern,et al.  Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review , 2015, Movement disorders : official journal of the Movement Disorder Society.

[19]  Richard Wade-Martins,et al.  Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.

[20]  K. Gamble,et al.  Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes , 2014, Molecular biology of the cell.

[21]  S. Love,et al.  Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease , 2014, Alzheimer's Research & Therapy.

[22]  T. Hortobágyi,et al.  Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.

[23]  K. Kosaka Lewy body disease and dementia with Lewy bodies , 2014, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[24]  Jia-Yi Li,et al.  Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats , 2014, Acta Neuropathologica.

[25]  H. Groenewegen,et al.  Stage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[26]  S. Gomperts Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies , 2014, Current Neurology and Neuroscience Reports.

[27]  W. M. van der Flier,et al.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.

[28]  Hao Wu,et al.  Complete morphologies of basal forebrain cholinergic neurons in the mouse , 2014, eLife.

[29]  C. Adler,et al.  The neurobiological basis of cognitive impairment in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[30]  C. Meshul,et al.  Presynaptic Alpha-Synuclein Aggregation in a Mouse Model of Parkinson's Disease , 2014, The Journal of Neuroscience.

[31]  G. Legname,et al.  In vitro aggregation assays for the characterization of α-synuclein prion-like properties , 2014, Prion.

[32]  M. Jahanshahi,et al.  The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia? , 2013, Neuroscience & Biobehavioral Reviews.

[33]  Nick C Fox,et al.  Molecular nexopathies: a new paradigm of neurodegenerative disease , 2013, Trends in Neurosciences.

[34]  Bin Zhang,et al.  Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.

[35]  D. Surmeier,et al.  Neuronal vulnerability, pathogenesis, and Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[36]  M. Nalls,et al.  A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. , 2013, JAMA neurology.

[37]  Mohamad Saad,et al.  Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. , 2013, Human molecular genetics.

[38]  Masato Hasegawa,et al.  Prion-like spreading of pathological α-synuclein in brain , 2013, Brain : a journal of neurology.

[39]  Daniela Boassa,et al.  Mapping the Subcellular Distribution of α-Synuclein in Neurons using Genetically Encoded Probes for Correlated Light and Electron Microscopy: Implications for Parkinson's Disease Pathogenesis , 2013, The Journal of Neuroscience.

[40]  H. Shill,et al.  Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains , 2013, Experimental Neurology.

[41]  L. White,et al.  Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease , 2012, Neurology.

[42]  K. Jellinger Neurobiology of cognitive impairment in Parkinson’s disease , 2012, Expert review of neurotherapeutics.

[43]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[44]  K. Berman,et al.  The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. , 2012, Brain : a journal of neurology.

[45]  J. Kordower,et al.  Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. , 2012, Brain : a journal of neurology.

[46]  Sachie K. Ogawa,et al.  Whole-Brain Mapping of Direct Inputs to Midbrain Dopamine Neurons , 2012, Neuron.

[47]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[48]  K. Jellinger Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts , 2012, Movement disorders : official journal of the Movement Disorder Society.

[49]  T. Uchihara,et al.  Pale Neurites, Premature α‐Synuclein Aggregates with Centripetal Extension from Axon Collaterals , 2012, Brain pathology.

[50]  E. Waxman,et al.  E46K Human α-Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment* , 2011, The Journal of Biological Chemistry.

[51]  D. Dickson,et al.  Neuropathology underlying clinical variability in patients with synucleinopathies , 2011, Acta Neuropathologica.

[52]  Constantinos Kallis,et al.  Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? , 2011, Brain : a journal of neurology.

[53]  C. Lowry,et al.  Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits , 2011, Psychopharmacology.

[54]  K. Blennow,et al.  The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia , 2011, International journal of geriatric psychiatry.

[55]  T. Iwatsubo,et al.  Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. , 2010, The Journal of biological chemistry.

[56]  B. Ghetti,et al.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. , 2010, Brain : a journal of neurology.

[57]  W. Schulz-Schaeffer The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[58]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[59]  A. Kakita,et al.  Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice , 2010, Acta Neuropathologica.

[60]  D. Dickson,et al.  Neuropathology of non-motor features of Parkinson disease. , 2009, Parkinsonism & related disorders.

[61]  J. Trojanowski,et al.  Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.

[62]  J. Callaway,et al.  Endogenous calcium buffering capacity of substantia nigral dopamine neurons. , 2009, Journal of neurophysiology.

[63]  T. Duka,et al.  α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  Dag Aarsland,et al.  Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology , 2009, Alzheimer disease and associated disorders.

[65]  K. Jellinger A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. , 2009, Biochimica et biophysica acta.

[66]  R. Burke,et al.  Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.

[67]  H. Shill,et al.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.

[68]  Ole Isacson,et al.  Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.

[69]  F. Fujiyama,et al.  Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum , 2009, The Journal of Neuroscience.

[70]  R. Hauser,et al.  Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.

[71]  P. Calabresi,et al.  Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies , 2008, Biological Psychiatry.

[72]  H. Budka,et al.  Nigral burden of α‐synuclein correlates with striatal dopamine deficit , 2008, Movement disorders : official journal of the Movement Disorder Society.

[73]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[74]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[75]  G. Halliday,et al.  The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.

[76]  Alain Dagher,et al.  Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years , 2008, Nature Medicine.

[77]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[78]  T. Iwatsubo,et al.  Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies , 2008, Experimental Neurology.

[79]  Michael L. Kramer,et al.  Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay. , 2008, BioTechniques.

[80]  Satoshi Orimo,et al.  Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease , 2008 .

[81]  K. Jellinger,et al.  Predictors of Survival in Dementia with Lewy Bodies and Parkinson Dementia , 2007, Neurodegenerative Diseases.

[82]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[83]  D. Westaway,et al.  Enhanced accumulation of phosphorylated α‐synuclein in double transgenic mice expressing mutant β‐amyloid precursor protein and presenilin‐1 , 2007 .

[84]  Michael L. Kramer,et al.  Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies , 2007, The Journal of Neuroscience.

[85]  E. Perry,et al.  Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.

[86]  J. Morris,et al.  Clinical phenotype of Parkinson disease dementia , 2006, Neurology.

[87]  H. Braak,et al.  Cognitive decline correlates with neuropathological stage in Parkinson's disease , 2006, Journal of the Neurological Sciences.

[88]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[89]  T. Duka,et al.  The neurotoxin, MPP+, induces hyperphosphorylation ofTau, in the presence of α-Synuclein, in SH-SY5Y neuroblastoma cells , 2006, Neurotoxicity Research.

[90]  G. Schellenberg,et al.  Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. , 2006, Archives of neurology.

[91]  J. E. Bell,et al.  Evidence of a breakdown of corticostriatal connections in Parkinson’s disease , 2005, Neuroscience.

[92]  E B Larson,et al.  Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both , 2005, Neurology.

[93]  Satoshi Orimo,et al.  Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease , 2005, Acta Neuropathologica.

[94]  T. Montine,et al.  Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease , 2005, Neurology.

[95]  D. Perl,et al.  Lewy-body formation is an aggresome-related process: a hypothesis , 2004, The Lancet Neurology.

[96]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[97]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[98]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[99]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[100]  B. Holdorff Friedrich Heinrich Lewy (1885–1950) and His Work , 2002, Journal of the history of the neurosciences.

[101]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[102]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[103]  T. Bayer,et al.  Lewy body variant of Alzheimer's disease: α‐synuclein in dystrophic neurites of Aβ plaques , 2000 .

[104]  D. Dickson,et al.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.

[105]  J. Gilbert,et al.  Lewy body and Alzheimer pathology in a family with the amyloid-β precursor protein APP717 gene mutation , 2000, Acta Neuropathologica.

[106]  J Q Trojanowski,et al.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[107]  J. Growdon,et al.  Clinical and quantitative pathologic correlates of dementia with Lewy bodies , 1999, Neurology.

[108]  P. Højrup,et al.  α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.

[109]  O. Hornykiewicz Biochemical aspects of Parkinson's disease , 1998, Neurology.

[110]  R. Levy,et al.  The Lewy-Body Variant of Alzheimer's Disease , 1993, British Journal of Psychiatry.

[111]  D. Dickson,et al.  Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease , 1991, Neurology.

[112]  K. Kosaka,et al.  Diffuse lewy body disease in Japan , 1990, Journal of Neurology.

[113]  L. Thal,et al.  The Lewy body variant of Alzheimer's disease , 1990, Neurology.

[114]  Y. Agid,et al.  Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.

[115]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[116]  E. Perry,et al.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[117]  T. Tomita,et al.  Dense core vesicles around the Lewy body in incidental Parkinson's disease: an electron microscopic study , 1977, Acta Neuropathologica.

[118]  L. Forno,et al.  Ultrastructure of Lewy bodies in the stellate ganglion , 1976, Acta Neuropathologica.

[119]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[120]  C. Heald Paralysis Agitans , 1932, Proceedings of the Royal Society of Medicine.

[121]  W. M. van der Flier,et al.  Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. , 2016, Journal of Alzheimer's disease : JAD.

[122]  E. Valente,et al.  Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models. , 2016, Parkinsonism & related disorders.

[123]  D. Dickson,et al.  Autosomal dominant Parkinson's disease caused by SNCA duplications. , 2016, Parkinsonism & related disorders.

[124]  A. Kakita,et al.  Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. , 2008, Brain : a journal of neurology.

[125]  D. Westaway,et al.  Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. , 2007, Journal of neuroscience research.

[126]  D. Dickson,et al.  Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. , 2007, Parkinsonism & related disorders.

[127]  Michael L. Kramer,et al.  Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[128]  A. Parent,et al.  Relationship between axonal collateralization and neuronal degeneration in basal ganglia. , 2006, Journal of neural transmission. Supplementum.

[129]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[130]  L. Mucke,et al.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[131]  T. Bayer,et al.  Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques. , 2000, Neuroreport.

[132]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[133]  F. Lewy Paralysis agitans. I. Pathologische Anatomie , 1912 .